Abstract:We have observed that of the 10 AAV serotypes, AAV6 is the most efficient in transducing primary human hematopoietic stem cells (HSCs), and that the transduction efficiency can be further increased by specifically mutating single surface-exposed tyrosine (Y) residues on AAV6 capsids. In the present studies, we combined the two mutations to generate a tyrosine double-mutant (Y705+731F) AAV6 vector, with which >70% of CD34(+) cells could be transduced. With the long-term objective of developing recombinant AAV vectors for the potential gene therapy of human hemoglobinopathies, we generated the wild-type (WT) and tyrosine-mutant AAV6 vectors containing the following erythroid cell-specific promoters: β-globin promoter (βp) with the upstream hyper-sensitive site 2 (HS2) enhancer from the β-globin locus control region (HS2-βbp), and the human parvovirus B19 promoter at map unit 6 (B19p6). Transgene expression from the B19p6 was significantly higher than that from the HS2-βp, and increased up to 30-fold and up to 20-fold, respectively, following erythropoietin (Epo)-induced differentiation of CD34(+) cells in vitro. Transgene expression from the B19p6 or the HS2-βp was also evaluated in an immuno-deficient xenograft mouse model in vivo. Whereas low levels of expression were detected from the B19p6 in the WT AAV6 capsid, and that from the HS2-βp in the Y705+731F AAV6 capsid, transgene expression from the B19p6 promoter in the Y705+731F AAV6 capsid was significantly higher than that from the HS2-βp, and was detectable up to 12 weeks post-transplantation in primary recipients, and up to 6 additional weeks in secondary transplanted animals. These data demonstrate the feasibility of the use of the novel Y705+731F AAV6-B19p6 vectors for high-efficiency transduction of HSCs as well as expression of the b-globin gene in erythroid progenitor cells for the potential gene therapy of human hemoglobinopathies such as β-thalassemia and sickle cell disease.

Exploitation of Hypoxia Regulatory Vectors for Gene Therapy of Renal Anemia

Development of a hypoxia-responsive vector for tumor-specific gene therapy

Construction and verification of a hypoxia-induced gene therapy vector targeting hepatocellular carcinoma

Reiterated Targeting Peptides on the Nanoparticle Surface Significantly Promote Targeted Vascular Endothelial Growth Factor Gene Delivery to Stem Cells.

Construction and identification of hypoxia regulatory reporter vectors

Construction and Identification of an Effective Hypoxia-Inducible Expression Vector

Retroviral Vector-Mediated Hypoxia-Regulated Neurotrophin-3 Gene Transfer Reduces Apoptosis Induced by Hypoxia in PC12 Cells

Nanoparticle Based Delivery of Hypoxia Regulated Vegf Transgene System Combined with Skms Engraftment: A Safer Approach to Treat Ischemic Cardiomyopathy

Construction and identification of the recombinant retroviral vector to carry out hypoxia-regulated expression of neurotrophin-3

A Novel Adenoviral Vector Which Mediates Hypoxia-Inducible Gene Expression Selectively in Neurons

Gene Therapy: Regulations, Ethics and Its Practicalities in Liver Disease

High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo.

Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression

Adeno-associated Viral Vector-Mediated Hypoxia-Regulated VEGF Gene Transfer Promotes Angiogenesis Following Focal Cerebral Ischemia in Mice

Development and clinical translation of ex vivo gene therapy

Gene Therapy for Rat Renal Anemia with Implantation of Erythropoietin-Transgenic Myoblasts

Adeno-Associated Virus Vector-Mediated Gene Delivery to the Vasculature and Kidney

Long-Term Reproducible Expression in Human Fetal Liver Hematopoietic Stem Cells with a UCOE-Based Lentiviral Vector

Feasibility of Hypoxia Inducible Factor Gene Transfer in Endothelial Progenitor Cell for Vascular Regeneration

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements

Carbon Nitride‐Based Sirna Vectors with Self‐Produced O2 Effects for Targeting Combination Therapy of Liver Fibrosis via HIF‐1α‐mediated TGF‐β1/Smad Pathway